Juvederm Vollure XC

FDA approves new Juvederm filler

Categories : Beauty Industry, Professional

A filler that can target deep wrinkles has been approved by the FDA. Even better: the fillers can last up to 18 months!

Allergan’s Juvederm Vollure XC is the first hyaluronic dermal filler that has been proven clinically effective for nasolabial folds and other moderate to severe wrinkles.

Allergan conducted clinical trials where 59% of the subjects saw a significant improvement in their “smile lines”. Unlike current fillers, which tend to last up to 1 year, the Juvederm Vollure XC was effective for 18 months.

Benefits of Juvederm Vollure XC

Juvéderm Vollure XC uses the Vycross technology found in Juvéderm Voluma XC (which targets cheeks) and Juvéderm Volbella XC (which targets lips) uses. Vycross blends different molecular weights of hyaluronic acid, contributing to the gel’s duration. However, this new formula is specially designed for the nasolabial folds, which is most popular dermal treatment area.

Known side effects and risks

“What’s exciting about Juvéderm Vollure XC is that it is the longest-lasting result shown in a clinical study in the nasolabial folds,” said Dr. Joely Kaufman, a board-certified dermatologist and clinical trial investigator.

The most common side effects of Juvederm Vollure XC were temporary injection site responses at the treatment site such as swelling, tenderness, bruising, firmness lumps/bumps, redness, pain, discoloration, and itching. Most of these side effects resolved within 1 week.

“The FDA approval of Juvederm Vollure XC demonstrates Allergan’s imperative to develop next-generation HA fillers designed to meet different patient needs,” said David Nicholson, Chief Research and Development Officer at Allergan. “This commitment to ongoing scientific research and development is one of the factors that make Juvederm the number one selling collection of dermal filler products.”